SCHEMBL24499460

SCHEMBL24499460

Fc1ccc(-c2cncc(CN3CCOc4ccccc43)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.62
DRD4 P21917 7/20 0.62
DRD3 P35462 7/20 0.62
HTR1A P08908 4/20 0.62
HTR2A P28223 1/20 0.62
HTR7 P34969 1/20 0.62
HTR2B P41595 1/20 0.62
TSHR P16473 2/20 0.47
HPGD P15428 1/20 0.47
AURKA O14965 1/20 0.41
FLT1 P17948 1/20 0.41
GCK P35557 1/20 0.41
FLT4 P35916 1/20 0.41
MAP3K11 Q16584 1/20 0.41
STK17A Q9UEE5 1/20 0.41
TNIK Q9UKE5 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
GRM5 P41594 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30530574 0.91 DRD2 (0.50) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL24499938 0.91 DRD2 (0.50) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL29597108 0.80 DRD2 (0.60) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL24499461 0.80 DRD2 (0.60) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL24499909 0.80 DRD2 (0.52) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL29597263 0.80 DRD2 (0.52) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL29598378 0.80 HDAC1 (0.45) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL24499948 0.80 HDAC1 (0.45) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL24499915 0.78 DRD2 (0.57) DRD2DRD4DRD3HTR1AHTR2A
SCHEMBL29597170 0.78 DRD2 (0.57) DRD2DRD4DRD3HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117920-A1 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER ORION CORPORATION (FI) 2022-06-09 WO disclosed